AR062894A1 - Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) - Google Patents
Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)Info
- Publication number
- AR062894A1 AR062894A1 ARP070104133A ARP070104133A AR062894A1 AR 062894 A1 AR062894 A1 AR 062894A1 AR P070104133 A ARP070104133 A AR P070104133A AR P070104133 A ARP070104133 A AR P070104133A AR 062894 A1 AR062894 A1 AR 062894A1
- Authority
- AR
- Argentina
- Prior art keywords
- tsh
- patient
- pharmaceutical composition
- therapeutic
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940088597 hormone Drugs 0.000 title abstract 2
- 239000005556 hormone Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 3
- 210000001685 thyroid gland Anatomy 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84607706P | 2006-09-19 | 2006-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062894A1 true AR062894A1 (es) | 2008-12-10 |
Family
ID=39018092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104133A AR062894A1 (es) | 2006-09-19 | 2007-09-19 | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100048455A1 (https=) |
| EP (1) | EP2063909B1 (https=) |
| JP (1) | JP2010503689A (https=) |
| AR (1) | AR062894A1 (https=) |
| BR (1) | BRPI0717077A2 (https=) |
| CA (1) | CA2663323A1 (https=) |
| DK (1) | DK2063909T3 (https=) |
| ES (1) | ES2396502T3 (https=) |
| MX (1) | MX2009002985A (https=) |
| PL (1) | PL2063909T3 (https=) |
| PT (1) | PT2063909E (https=) |
| SI (1) | SI2063909T1 (https=) |
| WO (1) | WO2008036271A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6255348B2 (ja) * | 2011-12-19 | 2017-12-27 | ジェンザイム・コーポレーション | 甲状腺刺激ホルモン組成物 |
| WO2019116048A1 (en) * | 2017-12-14 | 2019-06-20 | The London Psychiatry Centre | Treatment of psychiatric conditions such as resistant depression, bipolar disorder and/or major depressive disorder via application of repetitive transcranial magnetic stimulation with thyroid hormone treatment and/or quetiapine |
| CN113740523A (zh) * | 2021-09-14 | 2021-12-03 | 首都医科大学附属北京朝阳医院 | 一种基于量值溯源的tsh多系统赋值方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0228604A3 (en) * | 1985-12-11 | 1988-10-12 | Sloan-Kettering Institute For Cancer Research | Isolation of a gene encoding human thyrotropin beta subunit |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| CN1277633A (zh) * | 1997-09-22 | 2000-12-20 | 马里兰大学巴尔的摩分校 | 促甲状腺激素的突变体及其制备方法 |
| WO2000000222A1 (en) * | 1998-06-30 | 2000-01-06 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
| ITMI20011401A1 (it) * | 2001-07-02 | 2003-01-02 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei |
| US20080167223A1 (en) * | 2004-04-16 | 2008-07-10 | Mount Sinai School Of Medicine | Methods and Compositions for Using Tsh in the Inhibition of Tnf Activity |
-
2007
- 2007-09-18 DK DK07838433.6T patent/DK2063909T3/da active
- 2007-09-18 PL PL07838433T patent/PL2063909T3/pl unknown
- 2007-09-18 WO PCT/US2007/020221 patent/WO2008036271A1/en not_active Ceased
- 2007-09-18 SI SI200731102T patent/SI2063909T1/sl unknown
- 2007-09-18 ES ES07838433T patent/ES2396502T3/es active Active
- 2007-09-18 EP EP07838433A patent/EP2063909B1/en not_active Not-in-force
- 2007-09-18 PT PT78384336T patent/PT2063909E/pt unknown
- 2007-09-18 MX MX2009002985A patent/MX2009002985A/es active IP Right Grant
- 2007-09-18 JP JP2009528340A patent/JP2010503689A/ja active Pending
- 2007-09-18 BR BRPI0717077-7A patent/BRPI0717077A2/pt active Search and Examination
- 2007-09-18 CA CA002663323A patent/CA2663323A1/en not_active Abandoned
- 2007-09-18 US US12/441,836 patent/US20100048455A1/en not_active Abandoned
- 2007-09-19 AR ARP070104133A patent/AR062894A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010503689A (ja) | 2010-02-04 |
| CA2663323A1 (en) | 2008-03-27 |
| EP2063909A1 (en) | 2009-06-03 |
| WO2008036271A1 (en) | 2008-03-27 |
| EP2063909B1 (en) | 2012-10-24 |
| SI2063909T1 (sl) | 2013-02-28 |
| PL2063909T3 (pl) | 2013-05-31 |
| ES2396502T3 (es) | 2013-02-22 |
| US20100048455A1 (en) | 2010-02-25 |
| PT2063909E (pt) | 2013-01-15 |
| MX2009002985A (es) | 2009-04-01 |
| BRPI0717077A2 (pt) | 2013-11-26 |
| DK2063909T3 (da) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3623962B2 (ja) | ヒドロキソコバラミンの鼻中投与用医薬組成物 | |
| EP2635269B1 (en) | A combination composition | |
| ECSP056076A (es) | Sistema de suministro para droga y terapia celular | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| US20220072011A1 (en) | Treatments of accumulated fat with deoxycholic acid and salts thereof | |
| JP2001510795A5 (https=) | ||
| AU2017317950A1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
| SG146638A1 (en) | Pharmaceutical delivery system | |
| ES2383433T3 (es) | Formulación farmacéutica de apomorfina para administración bucal | |
| RU2009110273A (ru) | Способ уменьшения повреждения нервных клеток | |
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| KR20020046407A (ko) | 록소프로펜 함유 근육주사제 조성물 | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| JP5522939B2 (ja) | ヒト成長ホルモンパッチ製剤 | |
| BRPI0415322A (pt) | composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina | |
| BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| CN111773187B (zh) | 一种地塞米松磷酸钠冻干粉针剂 | |
| WO2011064769A1 (en) | Methods and pharmaceutical compositions for the treatment of hot flashes | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| KR20190117318A (ko) | 우수한 안정성을 갖는 데옥시콜린산 함유 주사제 조성물 및 이의 제조방법 | |
| MA28036A1 (fr) | Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil | |
| JP2016503406A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |